Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

HDAC inhibitor developer Acetylon raises $12.4mm in Series B round; closes at $28mm

Executive Summary

Acetylon Pharmaceuticals Inc. (targeting class II-selective histone deacetylases for the treatment of cancer, inflammation, neurodegeneration, genetic protein disorders, and infectious diseases) has raised $12.4mm towards a Series B financing that could total as much as $30mm according to the Form D filing. A group of 23 backers participated.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies